Drugs / LNA-i-miR-221
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04811898 | Jan 2019 → Dec 2021 | hepatocellular carcinoma, refractory plasma cell neoplasm | Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNA-i-miR-221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04811898 ↗ |
| Action | Inhibit | “This agent downregulated miR-221” PMID 37365583 ↗ Jun 2023 |
| Modality | Antisense oligonucleotide | “We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone.” PMID 37365583 ↗ Jun 2023 |
| Route | Intravenous | “LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)” NCT04811898 ↗ |